HOME > ARCHIVE

ARCHIVE

Shareholders' Meetings: Chugai's Merger with Roche Approved

July 8, 2002
Lasofoxifene Highly Useful for Postmenopausal Diseases

July 8, 2002
DIAGNOSTIC NEWS IN BRIEF

July 8, 2002
BUSINESS NEWS IN BRIEF

July 8, 2002
GL for Progressive Renal Disease Published by Korosho Study Group

July 8, 2002
WORLD NEWS IN BRIEF

July 8, 2002
Toyama Ties Up with Arrow of the UK to Develop Antifungals

July 8, 2002
NCCRI, FeRx to Collaborate on Gene Therapy Research

July 8, 2002
NBI to Reach Mid-term Goal with Int'l Strategic Products

July 8, 2002
Zeria, Yamanouchi Agree to Develop, Market Gastroprokinetic Z-338

July 8, 2002
GL for Low Back Pain Compiled

July 8, 2002
Sankyo, Kirin to Comarket Espo by March 2005

July 8, 2002
Vardenafil Improves ED in 73% of Diabetics

July 8, 2002
DTC Advertisements in Japan Discussed: JPMA Seminar

July 1, 2002
Report on New Drug Evaluation System Compiled by Study Group

July 1, 2002
BUSINESS NEWS IN BRIEF

July 1, 2002
RESEARCH AND DEVELOPMENT NEWS IN BRIEF

July 1, 2002
WEBSITE NEWS

July 1, 2002
DIAGNOSTIC NEWS IN BRIEF

July 1, 2002
CORPORATE ROUNDUP NEWS IN BRIEF

July 1, 2002

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…